- Home
- ELWS vs BCDA Comparison
ELWS vs BCDA Comparison
Compare ELWS & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELWS
- BCDA
- Stock Information
- Founded
- ELWS 2018
- BCDA N/A
- Country
- ELWS Japan
- BCDA United States
- Employees
- ELWS N/A
- BCDA N/A
- Industry
- ELWS
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- ELWS
- BCDA Health Care
- Exchange
- ELWS Nasdaq
- BCDA Nasdaq
- Market Cap
- ELWS 12.1M
- BCDA 11.3M
- IPO Year
- ELWS 2023
- BCDA N/A
- Fundamental
- Price
- ELWS $2.10
- BCDA $2.06
- Analyst Decision
- ELWS
- BCDA Strong Buy
- Analyst Count
- ELWS 0
- BCDA 1
- Target Price
- ELWS N/A
- BCDA $25.00
- AVG Volume (30 Days)
- ELWS 85.0K
- BCDA 62.9K
- Earning Date
- ELWS 09-30-2025
- BCDA 08-11-2025
- Dividend Yield
- ELWS N/A
- BCDA N/A
- EPS Growth
- ELWS N/A
- BCDA N/A
- EPS
- ELWS N/A
- BCDA N/A
- Revenue
- ELWS $3,083,071.00
- BCDA N/A
- Revenue This Year
- ELWS N/A
- BCDA N/A
- Revenue Next Year
- ELWS N/A
- BCDA N/A
- P/E Ratio
- ELWS N/A
- BCDA N/A
- Revenue Growth
- ELWS 145.52
- BCDA N/A
- 52 Week Low
- ELWS $1.64
- BCDA $1.63
- 52 Week High
- ELWS $10.50
- BCDA $3.26
- Technical
- Relative Strength Index (RSI)
- ELWS 39.07
- BCDA 56.99
- Support Level
- ELWS $2.22
- BCDA $1.90
- Resistance Level
- ELWS $3.16
- BCDA $1.99
- Average True Range (ATR)
- ELWS 0.25
- BCDA 0.08
- MACD
- ELWS -0.12
- BCDA 0.03
- Stochastic Oscillator
- ELWS 5.34
- BCDA 90.00
About ELWS Earlyworks Co. Ltd.
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).